Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer's Axitinib Disappoints As RCC Adjuvant Therapy

Executive Summary

An interim analysis has recommended stopping the Phase III ATLAS study because axitinib was failing to show it extended disease-free survival when used as adjuvant therapy in earlier-stage renal cell carcinoma patients. However, combination studies of axitinib with immuno-oncology agents will continue.

You may also be interested in...



Merck KGaA/SFJ's Abituzumab Evaluated For Left-Sided Metastatic Colon Cancer

SFJ Pharmaceuticals has taken on the late-stage clinical development of Merck KGaA's previously stalled MAb abituzumab, sharing the financial risk and evaluating patients with left-sided colorectal cancer.

Six New Drugs Get EMA Nod, Radius and Portola To Fight Rejections

Two products that the European Medicines Agency this week said should not be authorized for sale in the EU are already approved in the US.

Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC122880

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel